Updates
** Shares of drugmaker Corcept Therapeutics CORT.O soars as much as 91.7% to record high of $104.73
** Stock last up 83.6% at $100.29
** CORT says its experimental drug for ovarian cancer in combination with chemotherapy met the main goal of a late-stage trial
** Co says the drug, relacorilant, when combined with chemotherapy agent nab-paclitaxel, showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared with those treated with chemotherapy alone
** Canaccord Genuity analyst Edward Nash estimates peak sales of $1.3 billion for relacorilant by 2036
** Platinum-resistant ovarian cancer is a type of ovarian cancer that doesn't respond to platinum-based chemotherapy treatments, which are typically used as a first-line therapy
** Including session's moves, CORT shares more than double YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.